Immuno-PET of murine T cell reconstitution postadoptive stem cell transplantation using anti-CD4 and anti-CD8 cys-diabodies

Journal of Nuclear Medicine

Volumn 56, Issue 8, 2015, Pages 1258-1264

  Tavaré, Richard ^a   McCracken, Melissa N ^a   Zettlitz, Kirstin A ^a   Salazar, Felix B ^a   Olafsen, Tove ^a   Witte, Owen N ^a,b   Wu, Anna M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

89Zr; Antibody fragments; CD4+ and CD81 T cells; Hematopoietic stem cell transplantation; Immuno PET

Indexed keywords

CD4 CYSTEINE DIABODY ZR 89; CD8 CYSTEINE DIABODY ZR 89; DEFEROXAMINE; MALEIMIDE; RADIOISOTOPE; UNCLASSIFIED DRUG; ZIRCONIUM 89; CD4 ANTIGEN; CD8 ANTIGEN; MALEIMIDE DERIVATIVE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; ZIRCONIUM;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONJUGATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IN VIVO STUDY; ISOTOPE LABELING; LYMPH NODE; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; TISSUE DISTRIBUTION; AFFINITY CHROMATOGRAPHY; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; DIAGNOSTIC USE; IMMUNOTHERAPY; METABOLISM; PROCEDURES; TIME;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHROMATOGRAPHY, AFFINITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOTHERAPY; MALEIMIDES; MICE; MICE, INBRED C57BL; POSITRON-EMISSION TOMOGRAPHY; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES; TIME FACTORS; TISSUE DISTRIBUTION; ZIRCONIUM;

EID: 84938820449     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.153338     Document Type: Article

References (27)

1. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immuno-conjugates. Nat Biotechnol. 2005;23:1137-1146.
2. Wu AM. Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med. 2009;50:2-5.
3. Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol. 2012;30:3884-3892.
4. Wu AM. Engineered antibodies for molecular imaging of cancer. Methods. 2014;65:139-147.
5. Matsui K, Wang Z, McCarthy TJ, Allen PM, Reichert DE. Quantitation and visualization of tumor-specific T cells in the secondary lymphoid organs during and after tumor elimination by PET. Nucl Med Biol. 2004;31:1021-1031.
6. Pittet MJ, Grimm J, Berger CR, et al. In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci USA. 2007;104: 12457-12461.
7. Griessinger CM, Kehlbach R, Bukala D, et al. In vivo tracking of Th1 cells by PET reveals quantitative and temporal distribution and specific homing in lymphatic tissue. J Nucl Med. 2014;55:301-307.
8. Koya RC, Mok S, Comin-Anduix B, et al. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci USA. 2010;107:14286-14291.
9. 18F]FLT) PET imaging. Proc Natl Acad Sci USA. 2011;108: 18396-18399.
10. Nair-Gill E, Wiltzius SM, Wei XX, et al. PET probes for distinct metabolic pathways have different cell specificities during immune responses in mice. J Clin Invest. 2010;120:2005-2015.
11. 18F]-labeled 29-deoxycytidine analog. Nat Med. 2008;14:783-788.
12. 18F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med. 2010;51:340-346.
13. 18F]fluoro-9-beta-D-arabinofuranosylguanine: a novel agent for imaging T-cell activation with PET. Mol Imaging Biol. 2011;13:812-818.
14. McCracken MN, Gschweng EH, Nair-Gill E, et al. Long-term in vivo monitoring of mouse and human hematopoietic stem cell engraftment with a human positron emission tomography reporter gene. Proc Natl Acad Sci USA. 2013;110:1857-1862.
15. Yaghoubi SS, Campbell DO, Radu CG, Czernin J. Positron emission tomography reporter genes and reporter probes: gene and cell therapy applications. Thera-nostics. 2012;2:374-391.
16. Wirth T, Parker N, Yla-Herttuala S. History of gene therapy. Gene. 2013;525: 162-169.
17. De Oliveira SN, Ryan C, Giannoni F, et al. Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy. Hum Gene Ther. 2013;24:824-839.
18. Vatakis DN, Arumugam B, Kim SG, Bristol G, Yang O, Zack JA. Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression. Mol Ther. 2013;21:1055-1063.
19. Vatakis DN, Koya RC, Nixon CC, et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci USA. 2011;108:E1408-E1416.
20. Yang L, Baltimore D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc Natl Acad Sci USA. 2005;102:4518-4523.
21. Gschweng EH, McCracken MN, Kaufman ML, et al. HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice. Cancer Res. 2014;74:5173-5183.
22. Tavaré R, McCracken MN, Zettlitz KA, et al. Engineered antibody fragments for immuno-PET imaging of endogenous CD81 T cells in vivo. Proc Natl Acad Sci USA. 2014;111:1108-1113.
23. Kortt AA, Lah M, Oddie GW, et al. Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five-and ten-residue linkers form dimers and with zero-residue linker a trimer. Protein Eng. 1997;10:423-433.
24. Kelly MP, Lee FT, Tahtis K, et al. Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct. Cancer Biother Radiopharm. 2008;23: 411-423.
25. 64Cu-DOTA conjugation. Protein Eng Des Sel. 2014;27:317-324.
26. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932-945.
27. 124I-labeled anti-PSCA A11 minibody. J Nucl Med. 2014;55:452-459.